Get the Stockscreener App
1.84
0.00%
0.00
Fortress Biotech Inc stock is traded at $1.84, with a volume of 180.06K.
It is up +0.00% in the last 24 hours and up +0.55% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$1.84
Open:
$1.88
24h Volume:
180.06K
Relative Volume:
0.76
Market Cap:
$54.41M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.166
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
+0.55%
1M Performance:
+0.55%
6M Performance:
-15.98%
1Y Performance:
-2.65%
1-Day Range:
$1.80
$1.89
1-Week Range:
$1.79
$1.959
52-Week Range:
$1.325
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.84 | 54.11M | 80.97M | -78.31M | -129.56M | -11.08 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance
Checkpoint Therapeutics, Inc.(NasdaqCM: CKPT) dropped from S&P TMI Index - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpo - GuruFocus
Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics - marketscreener.com
Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News - GuruFocus
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - GlobeNewswire
Fortress Biotech, Inc. Announces Acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries Limited - Nasdaq
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - Benzinga
Fortress Biotech Cashes In: $28M Upfront Plus Royalties in Strategic Checkpoint Sale to Sun Pharma - Stock Titan
Checkpoint Therapeutics shareholders approve Sun Pharma merger By Investing.com - Investing.com India
One Fortress Biotech Insider Raised Stake By 26% In Previous Year - simplywall.st
Checkpoint Investor Sues for Info on Sale From Fortress to Sun - Bloomberg Law News
New Strong Sell Stocks for May 16th - The Globe and Mail
Q2 EPS Estimates for Fortress Biotech Raised by Roth Capital - Defense World
How the (FBIOP) price action is used to our Advantage - news.stocktradersdaily.com
Sun Pharma Q4 Consol Net PAT 21.5 Billion Rupees - marketscreener.com
Fortress Biotech Reports Q1 2025 Financial Highlights - TipRanks
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, S - GuruFocus
Fortress Biotech: Q1 Earnings Snapshot - CT Insider
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Fortress Biotech, Inc. SEC 10-Q Report - TradingView
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, Surpassing Estimates - GuruFocus
Fortress Biotech Reports First Quarter 2025 Financial Results an - GuruFocus
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch - Stock Titan
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Wednesday - Defense World
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewswire
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference | FBIO Stock News - GuruFocus
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference - The Manila Times
Renaissance Technologies LLC Has $356,000 Stock Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech, Inc. (NASDAQ:FBIO) Stock Position Boosted by Envestnet Asset Management Inc. - Defense World
Geode Capital Management LLC Increases Stock Position in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - The Globe and Mail
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - ADVFN
Sun Pharma shares in focus as co to acquire Checkpoint Therapeutics for $355 million - MSN
Fortress Biotech Board Member Resigns for New Role - TipRanks
When the Price of (FBIOP) Talks, People Listen - news.stocktradersdaily.com
Fortress Biotech (NASDAQ:FBIOP) Trading Down 2.1% – What’s Next? - Defense World
This Fortress Biotech Insider Increased Their Holding By 26% Last Year - Yahoo Finance
Roth Capital Forecasts Reduced Earnings for Fortress Biotech - Defense World
FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class ActionFBIO - MarketScreener
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
Journey Medical appoints new COO amid growth phase - Investing.com
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):